Diprospan suspension for injections syringe 1 ml. №1


Manufacturer: Belgium

Corticosteroid therapy is an adjunct rather than an alternative to traditional treatment. Dermatology diseases Atopic dermatitis (monetoid eczema), neurodermatitis, contact dermatitis, severe solar dermatitis, urticaria, lichen planus, insulin lipodystrophy, nesting alopecia, discoid erythematous lupus, psoriasis, keloid scars, common pemphigus, herpetic dermatitis, cystic acne. Rheumatic disease Rheumatoid arthritis, osteoarthritis, bursitis, tendonitis, tendinitis, peritendinitis, ankylosing spondylitis, epicondylitis, radiculitis, coccidinitis, sciatica, lumbago, torticollis, ganglion cyst, exostosis, fascitis, acute gouty arthritis, synovial cysts, Morton’s disease, inflammation of the cuboid bone, foot diseases, bursitis on the background of a hard corn, spurs, and stiffness of the big toe.



Diprospan Composition
1 ml of suspension contains:

Diprospan Active substances:
Betamethasone dipropionate 6.43 mg;
Betamethasone sodium phosphate 2.63 mg;

Diprospan Excipients:
Anhydrous disubstituted sodium phosphate;
Sodium chloride; Trilon B;
Polysorbate 80;
Benzyl alcohol;
Carboxymethylcellulose sodium salt;
Polyethylene glycol 4000;
Water for injections.

Pharmachologic effect
Diprospan – anti-allergic, anti-inflammatory.

Inhibits the release of interleukins 1 and 2, gamma-interferon from lymphocytes and macrophages, inflammatory mediators (eosinophils); induces the formation of lipocortins; reduces the metabolism of arachidonic acid.


Betamethasone disodium phosphate (an easily soluble component) is rapidly absorbed and provides a quick onset of effect. Betamethasone dipropionate, which has a slower absorption, provides a prolonged action.

Treatment of conditions and diseases in which GCS therapy allows an adequate clinical effect to be achieved (it should be borne in mind that for some diseases GCS therapy is additional and does not replace standard therapy):

Diseases of the musculoskeletal system and soft tissues, incl. rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, radiculitis, coccygodynia, sciatica, lumbago, torticollis, ganglion cyst, exostosis, fasciitis, foot diseases;

Allergic diseases, incl. bronchial asthma, hay fever (pollinosis), allergic bronchitis, seasonal or perennial rhinitis, drug allergies, serum sickness, insect bite reactions;

Dermatological diseases, incl. atopic dermatitis, coin-like eczema, neurodermatitis, contact dermatitis, severe photodermatitis, urticaria, lichen planus, insulin lipodystrophy, alopecia areata, discoid lupus erythematosus, psoriasis, keloid scars, pemphigus vulgaris, herpetic dermatitis;

Systemic connective tissue diseases, including systemic lupus erythematosus, scleroderma, dermatomyositis, periarteritis nodosa;

Hemoblastosis (palliative therapy of leukemia and lymphomas in adults, acute leukemia in children);

Primary or secondary adrenal cortex insufficiency (with the obligatory simultaneous use of mineralocorticoids);

Other diseases and pathological conditions requiring therapy with systemic corticosteroids (adrenogenital syndrome, ulcerative colitis, regional ileitis, malabsorption syndrome, lesions of the mucous membrane of the eye, if necessary, injecting the drug into the conjunctival sac, pathological changes in the blood, if necessary, using corticosteroids, nephritis, nephrotic syndrome).

Application during pregnancy and lactation
Do not use Diprospan during pregnancy.

If necessary, the use of Diprospan during lactation is recommended to stop breastfeeding.

Systemic mycoses;

Intravenous or subcutaneous administration;

For intra-articular administration: unstable joint, infectious arthritis;

Introduction into infected surfaces and into the intervertebral space;

Children under 3 years of age (presence of benzyl alcohol in the composition);

Hypersensitivity to the components of the drug;

Hypersensitivity to other GCS.